Journals / Journal of Contemporary Medicine / 2023 / Cilt: 13 Sayı: 3

Do Alterations In Serum Leptin, Adiponectin, Resistin, C Peptide, Il-10, Il-22 And Visfatin Levels Have An Impact On Survival In Patients With Advanced Stage Gastric And Colon Cancer?

Serum Leptin, Adiponektin, Resistin, C Peptid, IL-10, IL-22 Ve Visfatin Düzeylerinin İleri Evre Mide Ve Kolon Kanserli Hastalarda Sağkalıma Etkisi Var Mı?

Pages
451–458
Publication Date
2023-05-31
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Higher resistin and IL-10 levels were associated with shorter overall survival (p=0.035, p=0.14, respectively).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Abstract Background/Aims: Pathogenesis of cancer cachexia is not fully understood yet; however, adipocytokines are considered necessary in this context.
📊
Key Findings & Data:In this study, leptin, adiponectin, resistin, c-peptid, IL-10, IL-22, visfatin which are considered to be among markers of cancer cachexia were assessed.
💡
Conclusion & Impact:Higher resistin and IL-10 levels were associated with shorter overall survival (p=0.035, p=0.14, respectively).
🔬Design:Text.Serial.Journal
📍Scope:Comprehensive Sample
⚙️Variables:Cancer cachexia · Adipocytokines · Adiponectin

Abstract

Abstract Background/Aims: Pathogenesis of cancer cachexia is not fully understood yet; however, adipocytokines are considered necessary in this context. In this study, leptin, adiponectin, resistin, c-peptid, IL-10, IL-22, visfatin which are considered to be among markers of cancer cachexia were assessed. Methods: Fifty-three patients (34 male, 19 female) and 20 healthy people as a control group were included into this study. Blood samples were stored in deep freeze at -70 ºC and all of the samples were analyzed with appropriate biochemistry kit. Along with demographic data and laboratory tests results serum adiponectin, leptin, IL-10, IL-22, C peptide, resistin, visfatin levels were measured in 3 different time period both in patient and control group. Statistical data were evaluated by SPSS v22. Results: There was no statistically significant relationship between adipocytokine levels and progression-free survival. Higher resistin and IL-10 levels were associated with shorter overall survival (p=0.035, p=0.14, respectively). There was no significant relationship between other cytokines and overall survival. Multivariate analysis has shown that higher serum Ca 19.9 levels (OR 0.226, P=0.005), lower BMI (OR 5.726, p= 0.007), higher serum IL-10 levels (OR 0.329, p= 0.042) were factors showing an impact on progression-free survival; lower serum albumin levels (OR 0.282, p=0.013), higher serum LDH levels (OR 0,338, p=0.012), low BMI at diagnosis (OR 5.19, P<0.0005) were factors having an impact on overall survival. Conclusions: Our study detected an association between resistin, adipocytokine, and IL10 level and overall survival.

Özet

Öz Amaç: Kanser kaşeksisinin patogenezi henüz tam olarak anlaşılamamıştır; ancak adipositokinlerin bu bağlamda önemli olduğu düşünülmektedir. Bu çalışmada kanser kaşeksi belirteçlerinden sayılan leptin, adiponektin, resistin, c-peptid, IL-10, IL-22, visfatin değerlendirildi. Gereç ve Yöntem: Bu çalışmaya 53 hasta (34 erkek, 19 kadın) ve 20 sağlıklı kişi kontrol grubu olarak dahil edildi. Kan örnekleri -70 ºC'de derin dondurucuda saklandı ve tüm örnekler uygun biyokimya kiti ile analiz edildi. Hasta ve kontrol grubunda demografik veriler ve laboratuvar test sonuçları ile birlikte 3 farklı zaman diliminde serum adiponektin, leptin, IL-10, IL-22, C peptid, resistin, visfatin düzeyleri ölçüldü. İstatistiksel veriler SPSS v22 ile değerlendirildi. Bulgular: Adipositokin düzeyleri ile progresyonsuz sağkalım arasında istatistiksel olarak anlamlı bir ilişki yoktu. Daha yüksek resistin ve IL-10 seviyeleri, daha kısa genel sağkalım ile ilişkilendirildi (sırasıyla p=0.035, p=0.14). Diğer sitokinler ile genel sağkalım arasında anlamlı bir ilişki yoktu. Çok değişkenli analiz, daha yüksek serum Ca 19.9 düzeylerinin (OR 0.226, P=0.005), daha düşük BMI (OR 5.726, p= 0.007), daha yüksek serum IL-10 düzeylerinin (OR 0.329, p= 0.042) progresyonsuz sağkalıma etki gösteren faktörler olduğunu göstermiştir. Daha düşük serum albümin seviyeleri (OR 0.282, p=0.013), daha yüksek serum LDH seviyeleri (OR 0.338, p=0.012), tanı anında düşük BMI (OR 5.19, P<0.0005) genel sağkalımı etkileyen faktörlerdi. Sonuç: Çalışmamız, resistin, adipositokin ve IL10 düzeyi ile genel sağkalım arasında bir ilişki saptadı.

🔖

Cite This Article

Özlü, C., Dogu, G. G., Kargı, A., Akça, H., Demiray, A., Taşköylü, B. Y., Demiray, A. G., Değirmencioğlu, S., Yaren, A., Ergin, A. (2023). Do Alterations In Serum Leptin, Adiponectin, Resistin, C Peptide, Il-10, Il-22 And Visfatin Levels Have An Impact On Survival In Patients With Advanced Stage Gastric And Colon Cancer?. Journal of Contemporary Medicine, Cilt: 13 Sayı: 3, 451–458. https://ajindex.com/articles/1023831

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Deans C, Wigmore SJ. Systemic inflamation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care. 2005;8:265-269
  2. Hopkinson JB, Wright DNM, Foster C. Management of weigt loss and anorexia. Ann Oncol. 2008;19:289-293
  3. Bosaeus I. Nutritional support in multimodal therapy for cancer cachexia. Support Care Cancer. 2008;16(5):447-51
  4. Fearon KCH, Moses AGW. Cancer cachexia. International Journal of Cardiology. 2002;85:73–81
  5. Johnson G, Salle A, Lorimier G, Laccourreye L, Enon B, Blin V, et al. Cancer cachexia: measured and predicted resting energy expenditures for nutritional needs evaluation. Nutrition. 2008;24:443-450
  6. Yavuzsen T, Walsh D, Mellar P, Kirkova DJ, Jin T, LeGrand S et all. Components of the anorexia–cachexia syndrome: gastrointestinal symptom correlates of cancer anorexia. Support Care Cancer. 2009;17:1531–1541
  7. Seelaender M, Batista M Jr, Lira F, Silverio R, Rossi-Fanelli F. Inflammation in cancer cachexia: to resolve or not to resolve (is that the question?). Clin Nutr. 2012;31(4):562-6
  8. Hopkinson J, Corner J. Helping patients with advanced cancer live with concerns about eating: a challenge for palliative care professionals. J Pain Symptom Manage. 2006;31(4):293-305
  9. Bennani-Baiti N, Davis MP. Cytokines and cancer anorexia cachexia syndrome. Am J Hosp Palliat Care. 2008;25(5):407-11
  10. Rydén M, Arner P. Fat loss in cachexia--is there a role for adipocyte lipolysis? Clin Nutr. 2007;26(1):1-6
  11. Adya R, Tan BK, Chen J, Randeva HS. Visfatin and endothelial angiogenesis Cardiovasc Res. 2012;96(2): 223-226
  12. Jenab M, Riboli E, Cleveland RJ, Norat T, Rinaldi S, Nieters A, et al. Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European prospective investigation into cancer and nutrition. Int J Cancer. 2007;121:368–376
  13. Otani T, Iwasaki M, Sasazuki S, Inoue M, Tsugane S; Japan Public Health Center-based Prospective Study Group. Plasma C-peptide, insulin-like growth factor-I, insulin-like growth factor binding proteins and risk of colorectal cancer in a nested case-control study: the Japan public health center-based prospective study. Int J Cancer. 2007;120: 2007–2012
  14. Wei EK, Ma J, Pollak MN, Rifai N, Fuchs CS, Hankinson SE, et al. A prospective study of C-peptide, insulinlike growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev. 2005;14: 850–855
  15. Won HH, Kim JW, K